FI4058060T3 - Tyypin i interferonin esto systeemisen lupus erythematosuksen hoidossa - Google Patents

Tyypin i interferonin esto systeemisen lupus erythematosuksen hoidossa Download PDF

Info

Publication number
FI4058060T3
FI4058060T3 FIEP20804531.0T FI20804531T FI4058060T3 FI 4058060 T3 FI4058060 T3 FI 4058060T3 FI 20804531 T FI20804531 T FI 20804531T FI 4058060 T3 FI4058060 T3 FI 4058060T3
Authority
FI
Finland
Prior art keywords
ifnr
inhibitor
subject
use according
type
Prior art date
Application number
FIEP20804531.0T
Other languages
English (en)
Inventor
Anna Berglind
Gabriel Abreu
Lilia Pineda
Raj Tummala
Anca Askanase
Christophe Richez
Eric Morand
Ian Bruce
Philip Brohawn
Richard Furie
Sang-Cheol Bae
Yoshiya Tanaka
Victoria Werth
Ronald Van Vollenhoven
David Isenberg
Ed Vital
Michelle Kahlenberg
Rubana Kalyani
Kenneth Kalunian
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of FI4058060T3 publication Critical patent/FI4058060T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Claims (8)

1 EP4 058 060 TYYPIN | INTERFERONIN ESTO SYSTEEMISEN LUPUS ERYTHEMATOSUKSEN HOIDOSSA PATENTTIVAATIMUKSET
1. Tyypin | IFN-reseptorin (IFNR) estäjä käytettäväksi menetelmässä systeemisen punalupus erythematosuksen (SLE) hoitamiseksi sen tarpeessa olevalla hoidettavalla, jolloin menetelmä käsittää tyypin | interferoni (IFN) - reseptorin (IFNR) estäjän antamisen terapeuttisesti tehokkaana määränä hoidettavalle, jolloin hoidettavalla on lähtötilanteessa alhainen tyypin | IFN- geeniosa (IFNGS), jolloin IFNR:n estäjä on vähentää SLE:n tautiaktiivisuutta hoidettavalla, jolloin IFNR:n estäjä on anifrolumabi ja jolloin hoidettavan IFNGS lähtötilanteessa on mitattavissa 4 geenin kvantitatiivisella polymeraasiketjureaktioon perustuvalla testillä, jolloin kyseinen testi mittaa IFI27-, IF144-, IFI44L- ja RSAD2-ilmentymistä hoidettavan kokoveressä.
2. IFNR:n estäjä jonkin edellisen patenttivaatimuksen mukaiseen käyttöön, — jolloin hoidettavan SLE-tautiaktiivisuuden vähentäminen käsittää BILAG-pohjaisen lupuksen yhdistelmäarvioinnin (BICLA) vasteen hoidettavalla.
3. IFNR:n estäjä jonkin edellisen patenttivaatimuksen mukaiseen käyttöön, jolloin hoidettavalla on keskivaikea tai vaikea SLE.
4. IFNR:n estäjä patenttivaatimuksen 5 mukaiseen käyttöön, jolloin menetelmä käsittää IFNR:n estäjän antamisen 300 mg:n annoksena hoidettavalle.
5. IFNR:n estäjä patenttivaatimuksen 5 tai 6 mukaiseen käyttöön, joka käsittää IFNR:n estäjän annoksen antamisen hoidettavalle 4 viikon välein.
6. IFNR:n estäjä jonkin edellisen patenttivaatimuksen mukaiseen käyttöön, jolloin IFNR:n estäjää annetaan hoidettavalle laskimoon.
7. IFNR:n estäjä jonkin patenttivaatimuksen 1-5 mukaiseen käyttöön, jolloin IFNR:n estäjää annetaan hoidettavalle ihonalaisesti.
2 EP4 058 060
8. IFNR:n estäjä jonkin edellisen patenttivaatimuksen mukaiseen käyttöön, jolloin hoidettava on positiivinen dsDNA-, tuma- tai Smith-vasta-aineille lähtötilanteessa.
FIEP20804531.0T 2019-11-11 2020-11-11 Tyypin i interferonin esto systeemisen lupus erythematosuksen hoidossa FI4058060T3 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962933672P 2019-11-11 2019-11-11
US202063031848P 2020-05-29 2020-05-29
US202063089345P 2020-10-08 2020-10-08
PCT/EP2020/081770 WO2021094378A1 (en) 2019-11-11 2020-11-11 Type i interferon inhibition in systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
FI4058060T3 true FI4058060T3 (fi) 2025-03-21

Family

ID=73344065

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20804531.0T FI4058060T3 (fi) 2019-11-11 2020-11-11 Tyypin i interferonin esto systeemisen lupus erythematosuksen hoidossa

Country Status (16)

Country Link
US (1) US20220396630A1 (fi)
EP (2) EP4494712A3 (fi)
JP (1) JP2023501462A (fi)
KR (1) KR102766960B1 (fi)
CN (1) CN114728059A (fi)
AU (1) AU2020382850B2 (fi)
CA (1) CA3159568A1 (fi)
DK (1) DK4058060T3 (fi)
ES (1) ES3021878T3 (fi)
FI (1) FI4058060T3 (fi)
HU (1) HUE070947T2 (fi)
IL (1) IL292706A (fi)
PL (1) PL4058060T3 (fi)
PT (1) PT4058060T (fi)
TW (1) TW202133877A (fi)
WO (1) WO2021094378A1 (fi)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237647A (zh) * 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
KR20230110304A (ko) * 2020-11-18 2023-07-21 아스트라제네카 아베 스테로이드 절약
SMT202300382T1 (it) 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea
CN113278071B (zh) * 2021-05-27 2021-12-21 江苏荃信生物医药股份有限公司 抗人干扰素α受体1单克隆抗体及其应用
EP4545090A1 (en) * 2023-10-27 2025-04-30 Universität Leipzig Interferon-a receptor immune modulator for use as a medicament

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643237T3 (es) 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
SMT201700063T1 (it) 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
SI3769781T1 (sl) * 2015-08-19 2023-06-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1
EP3924383A1 (en) * 2019-02-15 2021-12-22 Astrazeneca AB Type i interferon-mediated disorders

Also Published As

Publication number Publication date
WO2021094378A9 (en) 2021-07-29
PT4058060T (pt) 2025-04-24
KR102766960B1 (ko) 2025-02-11
KR20220099985A (ko) 2022-07-14
EP4058060A1 (en) 2022-09-21
HUE070947T2 (hu) 2025-07-28
DK4058060T3 (da) 2025-03-17
ES3021878T3 (en) 2025-05-27
EP4494712A3 (en) 2025-03-26
CA3159568A1 (en) 2021-05-20
EP4058060B1 (en) 2025-02-19
IL292706A (en) 2022-07-01
PL4058060T3 (pl) 2025-07-28
WO2021094378A1 (en) 2021-05-20
US20220396630A1 (en) 2022-12-15
CN114728059A (zh) 2022-07-08
EP4494712A2 (en) 2025-01-22
JP2023501462A (ja) 2023-01-18
AU2020382850A1 (en) 2022-06-23
TW202133877A (zh) 2021-09-16
AU2020382850B2 (en) 2025-01-16

Similar Documents

Publication Publication Date Title
Abbasi et al. Strategies toward rheumatoid arthritis therapy; the old and the new
Terrier et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa‐2b plus ribavirin in severe hepatitis C virus–related vasculitis: a long‐term followup study of thirty‐two patients
Lawitz et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1
Liesegang Herpes zoster virus infection
Srisupa-Olan et al. Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders
Ogawa et al. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy
IL274272B1 (en) A safe and effective method for treating psoriatic arthritis with a specific anti-IL23 antibody
Lawitz et al. Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection
Adinolfi et al. Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemia
IL292706A (en) Type i interferon inhibition in systemic lupus erythematosus
Benitah et al. The use of biologic agents in the treatment of ocular manifestations of Behcet’s disease
Megna et al. IL-23 inhibitors in psoriasis: what have we learnt so far?
Furber et al. Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
Mackensen et al. Interferons and their potential in the treatment of ocular inflammation
Musallam et al. Steroids for deteriorating herpes simplex virus encephalitis
Yao et al. Tranylcypromine reduces herpes simplex virus 1 infection in mice
Garbarino et al. ABS0821 ANIFROLUMAB IN CUTANEOUS AND SYSTEMIC LUPUS ERYTHEMATOSUS: A REAL-LIFE EXPERIENCE
Nicoletta et al. Management of psoriatic patients in biologic treatment associated with infectious comorbidities
Janodia et al. Guttate psoriasis following COVID-19 infection
Martín et al. A recombinant adenovirus expressing ovine interferon tau prevents influenza virus-induced lethality in mice
Soliman et al. Predictors of sustained virological response in chronic hepatitis C patients treated with current direct acting antiviral drugs
Bain et al. Dynamics of interferon-specific gene expression in peripheral blood of interferon alfa-naive patients with genotype 1 chronic hepatitis C infection treated with albumin-interferon alfa
Lyakhovitsky et al. Dermatomyositis–lupuslike syndrome overlap under treatment with etanercept for rheumatoid arthritis
Revel et al. Interferons: cytokines in autoimmunity
Poordad et al. CONCOMITANT MEDICATION USE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY: 937